Video

Combining Local and Systemic Therapies in Liver Cancer

Author(s):

Ghassan K. Abou-Alfa, M.D.

Can local and systemic therapies be combined to treat liver cancer?

Ghassan K. Abou-Alfa, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of combining local and systemic therapy to treat liver cancer.

Currently, there is a divide between local (delivered directly to the tumor) therapy and systemic (given throughout the whole body) therapy in the treatment of liver cancer. However, Abou-Alfa said, "This is about marriage, not divorce," between the two treatment methods, and expects combination regimens to emerge on the scene.

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
February 21st 2025

How Patients With Cancer Can Avoid Counterfeit Therapeutics Online

Dr. Megan Menon
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
Marshall Morris, the founder of Dying Defiantly
December 8th 2022

Creating a Charity 8 Days After a Rare Cancer Diagnosis: Dying Defiantly Founder Shares His Story

Sailaja Darisipudi Andy Polhamus
After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.
Dr. Robert Jones is a professor of Clinical Cancer Research at The University of Glasgow School of Cancer Sciences, in Scotland.
February 15th 2025

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

Dr. Robert Jones
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Making Art From Cancer
December 10th 2020

Making Art From Cancer

Jessica Skarzynski
This week on the “CURE® Talks Cancer” podcast, we spoke with renowned street artist James Cochran about one of his art projects that was commissioned to symbolize the creativity and commitment of those who work tirelessly to eradicate cancer.
Dr. Eric K. Singhi currently serves as an assistant professor in both the Department of General Oncology and the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, Texas.
January 27th 2025

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

Ryan Scott
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.
Illustration of the liver.
January 25th 2025

Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC

Jordyn Sava
Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.